Rockefeller Capital Management
SABS icon

Rockefeller Capital Management’s SAB Biotherapeutics SABS Stock Holding History

Rockefeller Capital Management’s Portfolio SABS Stock Details SABS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-150
Closed – – 3543
2022
Q4 		$0 Hold
150
– – ﹤0.01% 4164
2022
Q3 		$1K Buy
150
+30
+25% +$298 ﹤0.01% 3777
2022
Q2 		$1K Buy
120
+10
+9% +$210 ﹤0.01% 4005
2022
Q1 		$4K Buy
110
+40
+57% +$1.85K ﹤0.01% 3441
2021
Q4 		$5K Buy
+70
New +$6.57K ﹤0.01% 3289

Other funds holding SABS

FPB
First PREMIER Bank Sioux Falls, South Dakota $619M AUM 20.21% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
V
Veritable Wilmington, Delaware $6.46B AUM 17.32% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $600M AUM 23.37% 1-Year Est. Return
IFAM
Institutional & Family Asset Management Fort Collins, Colorado $654M AUM 12.29% 1-Year Est. Return
MC
Meteora Capital Boca Raton, Florida $1.36B AUM 21.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Rockefeller Capital Management's SABS Position: Q1 2023 in Review

Rockefeller Capital Management sold out of SAB Biotherapeutics (SABS) in Q1 2023, closing a stake of 150 shares.

Rockefeller Capital Management first reported a position in SABS in Q4 2021 and held it in 5 quarters. The position peaked at $5K in Q4 2021. 39 funds tracked by Wall St. Rank hold SABS as of Q1 2023.

  • Rockefeller Capital Management reported no remaining SAB Biotherapeutics position as of Q1 2023 after selling out during the quarter.
  • Rockefeller Capital Management sold 150 SAB Biotherapeutics shares in Q1 2023.
  • Rockefeller Capital Management first reported a position in SAB Biotherapeutics in Q4 2021 and held it in 5 quarters.
  • Rockefeller Capital Management's SAB Biotherapeutics position peaked at $5K in Q4 2021.
  • 39 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q1 2023.

Based on Rockefeller Capital Management's 13F filing for Q1 2023, filed 16 May 2023.